Latest Media Releases (Page 5) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Proposed issue of securities - ALA (ASX:ALA)

To view the notification, download the attached PDF.

Arovella Therapeutics - Investor Presentation (ASX:ALA)

To view the presentation, download the attached PDF.

Arovella Therapeutics completes $1.65m placement (ASX:ALA)

-- Firm commitments received for $1.5 million Placement to new and existing institutional and sophisticated investors at $0.020 per share. -- Commitments from the board and management for an additi...read more

Arovella Therapeutics - Trading Halt (ASX:ALA)

The securities of Arovella Therapeutics Limited (‘ALA’) will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherwise, the secu...read more

Careteq receives $947K R&D Tax Refund (ASX:CTQ)

Careteq Limited (ASX: CTQ, “Careteq” or the “Group”) is pleased to announce that its cash position has been bolstered by the receipt of $947,123 from the Australian Taxation ...read more

Arovella Therapeutics - R&D Tax Incentive refund received (ASX:ALA)

MELBOURNE, AUSTRALIA 29 NOVEMBER 2022: Arovella Therapeutics Limited (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform, is leas...read more

Arovella Therapeutics: Europe Patent granted for iNKT Cell Therapy Platform (ASX:ALA)

MELBOURNE, AUSTRALIA 7 November 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat cancer, is plea...read more

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

Highlights for the quarter: Entered into a Strategic Collaboration with Imugene to combine Imugene’s onCARlytics platform and Arovella’s iNKT cell therapy platform in prec...read more

Careteq Q1-FY23 activities report and appendix 4C (ASX:CTQ)

Highlights: -- Assistive Living Technology revenues on track for solid growth in FY23 as Careteq secures 8 new customers in Q1 and expands sales pipeline to >$5M -- Careteq wins first Strong ...read more

Arovella to close its Perth OroMist R&D Facility (ASX:ALA)

Highlights: Strategic review underlines value in iNKT cell platform Decision to exit future OroMist based products drives annual cost saving of ~$1.5m Perth based R&D facil...read more

Arovella Therapeutics - Preclinical trial of ALA iNKT therapy and IMU onCARlytics (ASX:ALA)

HIGHLIGHTS: Arovella's CAR19-iNKT cell therapy will be combined with Imugene's onCARlytics (CF33- CD19) platform to target solid cancers in a pre-clinical trial. This trial w...read more

Arovella Therapeutics - Preliminary Final Report (ASX:ALA)

To view the Preliminary Final Report, download the attached PDF.

Careteq - Full Year Results Presentation (ASX:CTQ)

To view the presentation, download the attached PDF.

Careteq - Appendix 4G (ASX:CTQ)

To view the appendix, download the attached PDF.

Careteq - Full Year Results (ASX:CTQ)

Highlights: -- Rapidly growing sales pipeline and strong balance sheet put Careteq at a potential growth inflection point in the current financial year -- Currently managing >60 active sales ...read more

Viewing: 61 - 75 of 200 Previous | Next